文献速递心力衰竭与心肌病血脂与心血管预防

恶性左心室肥厚的种族差异与心力衰竭发病率:多队列研究

Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study.
PubMed 文献 · Circulation · 2020-01-14

BACKGROUND: A malignant subphenotype of left ventricular hypertrophy (LVH) has been described, in which minimal elevations in cardiac biomarkers identify individuals with LVH at high risk for developing heart failure (HF).…

要点

  • 恶性 LVH 定义为 ECG-LVH 伴 hs-cTnT≥6 ng/L 或 NT-proBNP≥100 pg/mL。
  • 黑人恶性 LVH 患病率为白人 3 倍,部分解释黑人心衰风险 excess。
  • 恶性 LVH 者心衰调整风险比 2.8,而 LVH 伴正常标志物者风险比 0.9。

核心结论

  • 恶性 LVH 患病率在黑人中更高,可能部分解释黑人与白人之间心衰风险的差异。

主要发现

  • 10 年随访期间,512 名(3.3%)参与者发生心衰,其中黑人男性 5.2%、白人男性 3.8%、黑人女性 3.2%、白人女性 2.2%。
  • 恶性 LVH 患病率在黑人男性和女性中均为白人男性和女性的 3 倍。
  • 与无 LVH 者相比,恶性 LVH 者心衰调整风险比为 2.8(95% CI,2.1-3.5),而 LVH 伴正常标志物者为 0.9(95% CI,0.6-1.5),各 race/sex 亚组结果相似。
  • 中介分析表明,黑人男性心衰 excess 风险的 33% 和黑人女性的 11% 可由恶性 LVH 患病率更高解释。
  • 发生心衰的黑人男性中,30.8% 基线时存在恶性 LVH,对应人群归因分数为 0.21。

关键数值与推荐

  • ECG-LVH 伴 hs-cTnT <6 ng/L 且 NT-proBNP <100 pg/mL 定义为 LVH 伴正常生物标志物。
  • ECG-LVH 伴 hs-cTnT ≥6 ng/L 或 NT-proBNP ≥100 pg/mL 定义为恶性 LVH。

临床怎么用

  • 对 ECG-LVH 患者可检测 hs-cTnT 和 NT-proBNP 以识别恶性 LVH 亚型,该亚型心衰风险显著升高。
  • 恶性 LVH 在黑人中患病率更高,识别该亚型可能有助于针对性预防心衰和减轻种族差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A malignant subphenotype of left ventricular hypertrophy (LVH) has been described, in which minimal elevations in cardiac biomarkers identify individuals with LVH at high risk for developing heart failure (HF). We tested the hypothesis that a higher prevalence of malignant LVH among blacks may contribute to racial disparities in HF risk. METHODS: Participants (n=15 710) without prevalent cardiovascular disease were pooled from 3 population-based cohort studies, the ARIC Study (Atherosclerosis Risk in Communities), the DHS (Dallas Heart Study), and the MESA (Multi-Ethnic Study of Atherosclerosis). Participants were classified into 3 groups: those without ECG-LVH, those with ECG-LVH and normal biomarkers (hs-cTnT (high sensitivity cardiac troponin-T) <6 ng/L and NT-proBNP (N-terminal pro-B-type natriuretic peptide) <100 pg/mL), and those with ECG-LVH and abnormal levels of either biomarker (malignant LVH). The outcome was incident HF. RESULTS: Over the 10-year follow-up period, HF occurred in 512 (3.3%) participants, with 5.2% in black men, 3.8% in white men, 3.2% in black women, and 2.2% in white women. The prevalence of malignant LVH was 3-fold higher among black men and women versus white men and women. Compared with participants without LVH, the adjusted hazard ratio for HF was 2.8 (95% CI, 2.1-3.5) in those with malignant LVH and 0.9 (95% CI, 0.6-1.5) in those with LVH and normal biomarkers, with similar findings in each race/sex subgroup. Mediation analyses indicated that 33% of excess hazard for HF among black men and 11% of the excess hazard among black women was explained by the higher prevalence of malignant LVH in blacks. Of black men who developed HF, 30.8% had malignant LVH at baseline, with a corresponding population attributable fraction of 0.21. The proportion of HF cases occurring among those with malignant LVH, and the corresponding population attributable fraction, were intermediate and similar among black women and white men and lowest among white women. CONCLUSIONS: A higher prevalence of malignant LVH may in part explain the higher risk of HF among blacks versus whites. Strategies to prevent development or attenuate risk associated with malignant LVH should be investigated as a strategy to lower HF risk and mitigate racial disparities.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Lewis AA, Ayers CR, Selvin E, et al. Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study. Circulation. 2020. PMID: 31931608. doi:10.1161/CIRCULATIONAHA.119.043628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。